Can chronic low-grade inflammation raise homocysteine and be reflected by hs-CRP?

Chronic low-grade inflammation acts as a critical driver of metabolic and vascular dysfunction by disrupting methylation pathways and promoting cellular stress.

Biochemical and mechanistic pathways

• Oxidative inactivation: Inflammation generates reactive oxygen species (ROS) that deplete glutathione (GSH) and oxidize the cobalamin (vitamin B12) cofactor of methionine synthase into an inactive cob(III)alamin state. This impairs the remethylation of homocysteine to methionine, causing homocysteine to accumulate.
• Methylation strain: The depletion of GSH forces a metabolic shift toward the transsulfuration pathway to synthesize glutathione from homocysteine. This diversion drains the methyl-donor pool and strains the methionine cycle to maintain S-adenosylmethionine (SAM) levels, functionally increasing methylation demand.
• Amplification loop: Increased methylation demand accelerates SAM consumption, generating excess S-adenosylhomocysteine (SAH), which is hydrolyzed into homocysteine. Crucially, elevated homocysteine promotes further ROS production and downregulates antioxidant systems, creating a pathological feedback loop that reinforces oxidative stress.

Clinical monitoring of systemic inflammation

• Role of hs-CRP: High-sensitivity C-reactive protein (hs-CRP) is a highly sensitive, liver-derived acute-phase protein. While standard CRP assays detect major infectious or inflammatory spikes, hs-CRP levels in the 1 to 10 mg/L range serve as a direct, validated clinical indicator of the chronic, low-grade systemic inflammation that underlies these methylation imbalances.

Bottom line

• Chronic low-grade inflammation—characterized by hs-CRP levels between 1 to 10 mg/L—elevates circulating homocysteine by inducing oxidative stress that biochemically inactivates methionine synthase and by driving a transsulfuration metabolic shift that increases cellular methylation demand.